Induced production of anti-etanercept antibody in collagen-induced arthritis

Yi,Hyoju; Kim,Juryun; Jung,Hyerin; Rim,Yeri Alice; Kim,Youngkyun; Jung,Seung Min; Park,Sung-Hwan; Ju,Ji Hyeon

doi:10.3892/mmr.2014.2127

Induced production of anti-etanercept antibody in collagen-induced arthritis

Authors:
- Hyoju Yi
- Juryun Kim
- Hyerin Jung
- Yeri Alice Rim
- Youngkyun Kim
- Seung Min Jung
- Sung-Hwan Park
- Ji Hyeon Ju
View Affiliations

Affiliations: Division of Rheumatology, Department of Internal Medicine, CiSTEM Laboratory, Convergent Research Consortium for Immunological Disease (CRCID), Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul 137-701, Republic of Korea
Published online on: April 9, 2014 https://doi.org/10.3892/mmr.2014.2127
Pages: 2301-2308

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Etanercept is a widespread biological drug for the treatment of rheumatoid arthritis, which inhibits tumor necrosis factor-α (TNF-α). Recently, the presence of antibodies targeting TNF-α inhibitors such as infliximab and adalimumab, was reported. However, few reports have studied etanercept in a mouse model of arthritis. We investigated the induction of anti-etanercept antibody production, along with the antibody's potential interfering effects on the biological function of etanercept, in mice with collagen-induced arthritis (CIA). CIA mice received an intraperitoneal injection of etanercept (25, 100 or 400 µg per mouse). The degree of inflammation and cartilage erosion was evaluated, and the number of osteoclasts in the ankle joints was assessed by TRAP staining. The level of pro-inflammatory cytokines in the serum was measured. To analyze the anti-osteoporotic effect of etanercept, microfocal computed tomography analyses of femurs and tibias were performed. Etanercept treatment decreased both the incidence and severity of arthritis in a dose-dependent manner, except for the highest dose of 400 µg. The mice that were treated with 25 and 100 µg etanercept showed an improvement in inflammation, cartilage damage, and even bone loss. However, mice treated with 400 µg etanercept showed no significant improvement in any of the tested parameters. Using a customized enzyme-linked immunosorbent assay (ELISA), the presence of the anti-etanercept antibody was detected in the serum in this treatment-refractory group. The therapeutic effect of etanercept was reduced in the CIA mice that developed the anti-etanercept antibody. In conclusion, the production of an anti-etanercept antibody can be induced in CIA mice, and this antibody can considerably reduce the anti-arthritic and anti‑osteoporotic effects of etanercept.

View Figures

View References

1	Aletaha D, Neogi T, Silman AJ, et al: 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis. 69:1580–1588. 2010. View Article : Google Scholar
2	Taylor PC: Pharmacology of TNF blockade in rheumatoid arthritis and other chronic inflammatory diseases. Curr Opin Pharmacol. 10:308–315. 2010. View Article : Google Scholar : PubMed/NCBI
3	Scott DL and Kingsley GH: Tumor necrosis factor inhibitors for rheumatoid arthritis. N Engl J Med. 355:704–712. 2006. View Article : Google Scholar : PubMed/NCBI
4	Moreland LW, Schiff MH, Baumgartner SW, et al: Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial Ann Intern Med. 130:478–486. 1999.PubMed/NCBI
5	Bathon JM, Martin RW, Fleischmann RM, et al: A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med. 343:1586–1593. 2000. View Article : Google Scholar : PubMed/NCBI
6	Moreland LW, Baumgartner SW, Schiff MH, et al: Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med. 337:141–147. 1997. View Article : Google Scholar : PubMed/NCBI
7	Elliott MJ, Maini RN, Feldmann M, et al: Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet. 344:1105–1110. 1994. View Article : Google Scholar : PubMed/NCBI
8	van den Berg WB, Joosten LA and van de Loo FA: TNF alpha and IL-1 beta are separate targets in chronic arthritis. Clin Exp Rheumatol. 17:S105–S114. 1999.PubMed/NCBI
9	Kang KY, Lee KY, Kwok SK, et al: The change of bone mineral density according to treatment agents in patients with ankylosing spondylitis. Joint Bone Spine. 78:188–193. 2011. View Article : Google Scholar
10	Ju JH, Kang KY, Kim IJ, et al: Visualization and localization of rheumatoid knee synovitis with FDG-PET/CT images. Clin Rheumatol. 27(Suppl 2): S39–S41. 2008. View Article : Google Scholar : PubMed/NCBI
11	Wolfe F and Michaud K: Towards an epidemiology of rheumatoid arthritis outcome with respect to treatment: randomized controlled trials overestimate treatment response and effectiveness. Rheumatology (Oxford). 44 Suppl 4:iv18–iv22. 2005. View Article : Google Scholar
12	National Institute for Health and Clinical Excellence. Adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis. http://www.nice.org.uk/nicemedia/live/11867/37914/37914.pdf. Accessed June 8, 2012
13	Genovese MC, Bathon JM, Martin RW, et al: Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Arthritis Rheum. 46:1443–1450. 2002.PubMed/NCBI
14	O’Dell JR: Treating rheumatoid arthritis early: a window of opportunity? Arthritis Rheum. 46:283–285. 2002.PubMed/NCBI
15	Ju JH, Cho ML, Jhun JY, et al: Oral administration of type-II collagen suppresses IL-17-associated RANKL expression of CD4⁺ T cells in collagen-induced arthritis. Immunol Lett. 117:16–25. 2008. View Article : Google Scholar : PubMed/NCBI
16	Yamaguchi N, Ohshima S, Umeshita-Sasai M, et al: Synergistic effect on the attenuation of collagen induced arthritis in tumor necrosis factor receptor I (TNFRI) and interleukin 6 double knockout mice. J Rheumatol. 30:22–27. 2003.PubMed/NCBI
17	Kobayashi K, Takahashi N, Jimi E, et al: Tumor necrosis factor alpha stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction. J Exp Med. 191:275–286. 2000. View Article : Google Scholar : PubMed/NCBI
18	Hsu H, Lacey DL, Dunstan CR, et al: Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci USA. 96:3540–3545. 1999. View Article : Google Scholar : PubMed/NCBI
19	Boyle WJ, Simonet WS and Lacey DL: Osteoclast differentiation and activation. Nature. 423:337–342. 2003. View Article : Google Scholar : PubMed/NCBI
20	Lacey DL, Timms E, Tan HL, et al: Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell. 93:165–176. 1998. View Article : Google Scholar : PubMed/NCBI
21	Reagan-Shaw S, Nihal M and Ahmad N: Dose translation from animal to human studies revisited. FASEB J. 22:659–661. 2008. View Article : Google Scholar : PubMed/NCBI
22	Finckh A, Simard JF, Gabay C and Guerne PA; SCQM physicians. Evidence for differential acquired drug resistance to anti-tumour necrosis factor agents in rheumatoid arthritis. Ann Rheum Dis. 65:746–752. 2006. View Article : Google Scholar : PubMed/NCBI
23	Haraoui B, Cameron L, Ouellet M and White B: Anti-infliximab antibodies in patients with rheumatoid arthritis who require higher doses of infliximab to achieve or maintain a clinical response. J Rheumatol. 33:31–36. 2006.PubMed/NCBI
24	Elkayam O, Burke M, Vardinon N, et al: Autoantibodies profile of rheumatoid arthritis patients during treatment with infliximab. Autoimmunity. 38:155–160. 2005. View Article : Google Scholar : PubMed/NCBI
25	Atzeni F, Doria A, Ghirardello A, et al: Organ-specific autoantibodies in patients with rheumatoid arthritis treated with adalimumab: a prospective long-term follow-up. Autoimmunity. 41:87–91. 2008. View Article : Google Scholar : PubMed/NCBI
26	Dore RK, Mathews S, Schechtman J, et al: The immunogenicity, safety, and efficacy of etanercept liquid administered once weekly in patients with rheumatoid arthritis. Clin Exp Rheumatol. 25:40–46. 2007.PubMed/NCBI
27	Keystone EC, Schiff MH, Kremer JM, et al: Once-weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 50:353–363. 2004. View Article : Google Scholar
28	Emi Aikawa N, de Carvalho JF, Artur Almeida Silva C and Bonfá E: Immunogenicity of anti-TNF-alpha agents in autoimmune diseases. Clin Rev Allergy Immunol. 38:82–89. 2010.PubMed/NCBI